Preparation and characterization of the myricetin-loaded solid lipid nanoparticles decorated with folic acid-bound chitosan and evaluation of its antitumor and anti-angiogenic activities in vitro and in vivo in mice bearing tumor models

Abstract Myricetin is a flavonoid with anticancer properties. This study aimed to formulate myricetin in the form of solid lipid nanoparticles (SLN), decorated chitosan (CS) and active-targeted folic acid (FA). After characterization, vitro release, cytotoxicity, antioxidant, ability formulation induce apoptosis using flow cytometry, fluorescent microscopy, real-time qPCR were examined. Then vivo anti-angiogenesis on chick chorioallantoic membrane (CAM) antitumor activities mice bearing tumor models investigated. The present showed that size 310 nm zeta potential + 30 mV acceptable for oral administration. Michaelis–Menten model fitted drug release pattern lag during 144 h study. cytotoxicity assay myricetin-SLN-CS-FA significantly killed cancer cells at concentrations 6.25, 12.5, 25, 50 100 µg/mL (* p < 0.05, ** 0.01, *** 0.001). highest level was shown concentration 45 µg/ml studies. These results properties dose-dependent manner. also indicated exerted its cytotoxic effect by activating genes. DPPH, ABTS, FRAP studies demonstrated significant antioxidant anti-angiogenic formulations depicted CAM decrease number length vessels 0.001), affect VEGF VEGFR, genes involved angiogenesis (** statistically effects reducing volume 0.05 H&E staining liver monitoring animal weights safety formulation. analysis mRNA expression exerts modulating inflammatory oxidative responses tissues.